Sugi Predict

Sugi Predict / Compounds / SCHEMBL6036966

SCHEMBL6036966

SCHEMBL6036966

O=C(CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21)Nc1ccc(C(=O)O)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 6/20 0.73
▸ CA1 P00915 6/20 0.73
▸ CA2 P00918 6/20 0.73
▸ CA9 Q16790 6/20 0.73
▸ PTPRF P10586 2/20 0.63
▸ PTPN2 P17706 2/20 0.63
▸ PTPN1 P18031 2/20 0.63
▸ TDP1 Q9NUW8 5/20 0.62
▸ PKM P14618 2/20 0.62
▸ MEN1 O00255 1/20 0.62
▸ ABL1 P00519 1/20 0.62
▸ LMNA P02545 1/20 0.62
▸ IDE P14735 1/20 0.62
▸ MAPK1 P28482 1/20 0.62
▸ KMT2A Q03164 1/20 0.62
▸ RIN1 Q13671 1/20 0.62
▸ L3MBTL1 Q9Y468 1/20 0.62
▸ SLC6A3 Q01959 2/20 0.57
▸ ITGB1 P05556 1/20 0.53
▸ ITGA4 P13612 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18391007 1.00 CA12 (0.73) CA12CA1CA2CA9PTPRF
SCHEMBL3620407 1.00 CA12 (0.73) CA12CA1CA2CA9PTPRF
SCHEMBL565442 0.99 CA12 (0.72) CA12CA1CA2CA9PTPRF
SCHEMBL14253654 0.90 CA12 (0.74) CA12CA1CA2CA9PTPRF
SCHEMBL25374435 0.90 CA12 (0.74) CA12CA1CA2CA9PTPRF
SCHEMBL565441 0.90 CA12 (0.74) CA12CA1CA2CA9PTPRF
SCHEMBL19940249 0.88 CA12 (0.74) CA12CA1CA2CA9PTPRF
SCHEMBL21524959 0.88 CA12 (0.78) CA12CA1CA2CA9PTPRF
SCHEMBL18329586 0.88 CA12 (0.74) CA12CA1CA2CA9PTPRF
SCHEMBL12059002 0.88 CA12 (0.74) CA12CA1CA2CA9PTPRF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260130936-A1 COMPOSITIONS COMPRISING AN ACTIVE INGREDIENT MIXTURE COMPRISING SILICON AND BIOTIN AND METHODS OF USE NUTRITION21 LLC (US) 2026-05-14 — — US disclosed
US-20250170171-A1 COMPOSITIONS COMPRISING AN ACTIVE INGREDIENT MIXTURE COMPRISING SILICON AND BIOTIN AND METHODS OF USE Nutrition21, LLC 2025-05-29 — — US disclosed
EP-4486341-A1 COMPOSITIONS COMPRISING AN ACTIVE INGREDIENT MIXTURE COMPRISING SILICON AND BIOTIN AND METHODS OF USE Nutrition 21, LLC (US) 2025-01-08 — — EP disclosed
WO-2023164272-A1 COMPOSITIONS COMPRISING AN ACTIVE INGREDIENT MIXTURE COMPRISING SILICON AND BIOTIN AND METHODS OF USE Nutrition21, LLC (US) 2023-08-31 — — WO disclosed
CN-114890548-B Method for treating aquaculture tail water 广西壮族自治区海洋环境监测中心站 2023-01-06 — — CN disclosed
CN-114890548-A Method for treating aquaculture tail water 广西壮族自治区海洋环境监测中心站 2022-08-12 — — CN disclosed
WO-2015021990-A1 RNA PROBING METHOD AND REAGENTS UNIVERSITY OF COPENHAGEN (DK) 2015-02-19 — — WO disclosed
US-7078013-B2 Pretargeting methods and compounds ALETHEON PHARMACEUTICALS, INC. (US) 2006-07-18 — — US disclosed
US-20040241172-A1 Pretargeting methods and compounds NEORX CORPORATION (US) 2004-12-02 — — US disclosed
US-6709652-B2 RADIOACTIVE LABELING OF BIOTIN NEORX CORPORATION 2004-03-23 — — US disclosed
EP-0743956-A1 PRETARGETING METHODS AND COMPOUNDS NeoRx (US) 1996-11-27 — — EP disclosed
US-5578287-A COMPOUNDS FOR MEDICAL DIAGNOSIS AND TARGETS AND ANTIBODIES NEORX CORPORATION (US) 1996-11-26 — — US disclosed
EP-0736035-A1 PRETARGETING METHODS AND COMPOUNDS NEORX CORPORATION (US) 1996-10-09 — — EP disclosed
EP-0732943-A1 THREE-STEP PRETARGETING METHODS AND COMPOUNDS NEORX CORPORATION (US) 1996-09-25 — — EP disclosed
US-5541287-A DIAGNOSIS USING CYCLIC TRIPEPTIDES WITH NITROBENZYL 1,4,7,10-TETRAAZACYCLODODECANE-N,N*,N**,N***TETRAACETIC ACID BIOTIN CONJUGATE FORMED BY ALKYLATION AND MULTISTAGE PROCESS NEORX CORPORATION (US) 1996-07-30 — — US disclosed
WO-1995015978-A1 PRETARGETING METHODS AND COMPOUNDS NEORX CORPORATION (US) 1995-06-15 — — WO disclosed
WO-1995015335-A2 PRETARGETING METHODS AND COMPOUNDS NEORX CORPORATION (US) 1995-06-08 — — WO disclosed
WO-1995014493-A1 THREE-STEP PRETARGETING METHODS AND COMPOUNDS NEORX CORPORATION (US) 1995-06-01 — — WO disclosed
EP-0646019-A1 PRETARGETING METHODS AND COMPOUNDS NEORX CORPORATION (US) 1995-04-05 — — EP disclosed
WO-1993025240-A2 PRETARGETING METHODS AND COMPOUNDS NEORX CORPORATION (US) 1993-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040241172-A1 Pretargeting methods and compounds HLCS, BTD, STRA6 CA12 2023/4885CA1 3380/4885CA2 4716/4885
US-20250170171-A1 COMPOSITIONS COMPRISING AN ACTIVE INGREDIENT MIXTURE COMPRISING SILICON AND BIOTIN AND METHODS OF USE SRM, SMS, ASS1 CA12 2565/4885CA1 1502/4885CA2 1876/4885
US-20260130936-A1 COMPOSITIONS COMPRISING AN ACTIVE INGREDIENT MIXTURE COMPRISING SILICON AND BIOTIN AND METHODS OF USE SMS, SRM, PPIP5K2 CA12 2896/4885CA1 2042/4885CA2 1412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.